Acta Med. 2026, 69: 75-80
https://doi.org/10.14712/18059694.2026.22
Refractory Form of Chronic Idiopathic Demyelinating Polyneuropathy with Rituximab Effect: A Case Report
References
1. M, Martin-Aguilar L, Collet-Vidiella R, Querol L, Pascual-Goñi E. A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy. Front Immunol. 2025 Apr; 16: 1575464.
<https://doi.org/10.3389/fimmu.2025.1575464>
<PubMed>
2. Y, Zhang Y, Su X, Zheng C, Lu Z. The comparison of MRN, electrophysiology and progression among typical CIDP and atypical CIDP subtypes. Sci Rep. 2020 Oct; 10(1): 16697.
<https://doi.org/10.1038/s41598-020-73104-1>
<PubMed>
3. Y, Hu J, Sun C, et al. Insights into refractory chronic inflammatory demyelinating polyneuropathy: a comprehensive real-world study. Front Neurol. 2024 Jan; 15: 1326874.
<https://doi.org/10.3389/fneur.2024.1326874>
<PubMed>
4. J, Barrett MJ, Ensrud E, et al. Refractory CIDP: Clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci. 2020 Nov; 418: 117098.
<https://doi.org/10.1016/j.jns.2020.117098>
5. S, Mazibrada G, Irani SR, Jacob A, Yudina A. The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. J Neuroimmune Pharmacol. 2021 Dec; 16(4): 806–17.
<https://doi.org/10.1007/s11481-021-10004-9>
<PubMed>
6. MC, van Doorn PA, Kuiwaard K, et al. Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: A survay among Dutch neurologists. J Peripher Nerv Syst. 2020; 25: 247–55.
<https://doi.org/10.1111/jns.12399>
<PubMed>
7. L, Siles AM, Alba-Rovira R, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep. 2017 Oct; 7(1): 14411.
<https://doi.org/10.1038/s41598-017-14853-4>
<PubMed>
8. OJM, Marques W, Goncalves MVM, et al. Brazilian Academy of Neurology recommendation for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Arq Neuropsiquiatr. 2025; 83(7): 1–19.
9. YA. Chronic inflammatory demyelinating polyradiculoneuropathy: Current therapeutic approach and future outlooks. Immunotargets Ther. 2024 Feb; 13: 99–110.
<https://doi.org/10.2147/ITT.S388151>
<PubMed>
10. ED, Ceredaq D, Fusco MI, et al. Eculizumab as a disease-modifying therapy in chronic inflammatory demyalinating polyneuropathy (CIDP): A case report. J Peripher Nerv Syst. 2025 Mar; 30(1): e70010.
<https://doi.org/10.1111/jns.70010>
<PubMed>
11. Yoshikawa M, Goto Y, Tsutsumi M, Hirahara R, Ide T, Shichijo C, Suzuyama K, Koike H. Real-World Application of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Intern Med. 2026 Mar 17.
<https://doi.org/10.2169/internalmedicine.6845-25>
